<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275170</url>
  </required_header>
  <id_info>
    <org_study_id>7655-005</org_study_id>
    <nct_id>NCT01275170</nct_id>
  </id_info>
  <brief_title>A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)</brief_title>
  <official_title>A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Subjects With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part study of the pharmacokinetics (PK) of MK-7655. In Part I, the PK of a single
      125 mg dose of MK-7655 given in combination with 250 mg of PRIMAXIN® (imipenem + cilastatin)
      will be determined in participants with impaired renal function and matched control
      participants. In Part II, the potential for renal insufficiency to affect non-renal clearance
      mechanisms will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2011</start_date>
  <completion_date type="Actual">March 5, 2012</completion_date>
  <primary_completion_date type="Actual">March 5, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf) of MK-7655 in Combination With PRIMAXIN®</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dialysis Clearance (CLD) of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)</measure>
    <time_frame>1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours postdose</time_frame>
    <description>The CLD of MK-7655 was determined in ESRD/HD participants for 4.5 hours during HD. The formula for calculating CLD was: CLd = (1-Hct)*QB*[(pre-dialyzer concentration - post-dialyzer concentration) / (pre-dialyzer concentration)] where QB=350 mL/min and Hct=hematocrit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extraction Coefficient of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)</measure>
    <time_frame>1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours postdose</time_frame>
    <description>The extraction coefficient of MK-7655 was determined in ESRD/HD participants for 4.5 hours during HD. The formula for calculating extraction coefficient was: Extraction Coefficient = ABS[100*(post-dialyzer concentration - pre-dialyzer concentration) / pre-dialyzer concentration].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Concentration at End of Infusion (Ceoi) of MK-7655 in Combination With PRIMAXIN®</measure>
    <time_frame>At 0.5 hours postdose</time_frame>
    <description>Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Predicted Clearance (CLpred) of MK-7655 in Combination With PRIMAXIN®</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>CLpred is the predicted apparent total body clearance of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Predicted Volume of Distribution During the Terminal Phase (VZpred) of MK-7655 in Combination With PRIMAXIN®</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>VZpred is the predicted volume of distribution during the terminal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time of Maximum Plasma Concentration (Tmax) of MK-7655 in Combination With PRIMAXIN®</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent Plasma Half-life (t½) of MK-7655 in Combination With PRIMAXIN®</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC0-inf of Imipenem in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Ceoi of Imipenem in Combination With MK-7655</measure>
    <time_frame>At 0.5 hours postdose</time_frame>
    <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: CLpred of Imipenem in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. CLpred is the predicted apparent total body clearance of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: VZpred of Imipenem in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. VZpred is the predicted volume of distribution during the terminal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax of Imipenem in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent t½ of Imipenem in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC0-inf of Cilastin in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Ceoi of Cilastin in Combination With MK-7655</measure>
    <time_frame>At 0.5 hours postdose</time_frame>
    <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: CLpred of Cilastin in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. CLpred is the predicted apparent total body clearance of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: VZpred of Cilastin in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. VZpred is the predicted volume of distribution during the terminal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax of Cilastin in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent t½ of Cilastin in Combination With MK-7655</measure>
    <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
    <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Renal Clearance (CLR) of MK-7655 in Urine</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
    <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: CLR of Imipenem in Urine</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
    <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: CLR of Cilastin in Urine</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
    <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Plasma AUC0-∞ of Caffeine as a Probe Substrate of Cytochrome P450 Enzyme (CYP)1A2</measure>
    <time_frame>Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose</time_frame>
    <description>Caffeine was selected as a substrate of CYP1A2. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Plasma AUC0-∞ of Midazolam as a Probe Substrate of Cytochrome P450 Enzyme (CYP)3A4</measure>
    <time_frame>Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose</time_frame>
    <description>Midazolam was selected as a substrate of CYP3A4. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Plasma AUC0-∞ of Omeprazole as a Probe Substrate of Cytochrome P450 Enzyme (CYP)2C19</measure>
    <time_frame>Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose</time_frame>
    <description>Omeprazole was selected as a substrate of CYP2C19. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Percentage of Participants With ≥1 Adverse Events (AEs)</measure>
    <time_frame>Up to 14 days after the last dose of study drug in Part 2 (up to 11 weeks)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Infectious Disease</condition>
  <arm_group>
    <arm_group_label>Panel A Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subset of healthy control participants were matched specifically to participants in Panel A and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an eGFR of 30 to 50 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subset of healthy control participants were matched specifically to participants in Panel C and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an eGFR &lt;30 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subset of healthy control participants were matched specifically to participants in Panel E and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subset of healthy control participants were matched specifically to participants in Panel G and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-7655</intervention_name>
    <description>125 mg intravenous (IV) over 30 minutes as a single dose</description>
    <arm_group_label>Panel A Mild Renal Impairment</arm_group_label>
    <arm_group_label>Panel B Healthy Participants</arm_group_label>
    <arm_group_label>Panel C Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Panel D Healthy Participants</arm_group_label>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <other_name>RELEBACTAM®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem + Cilastatin</intervention_name>
    <description>250 mg IV over 30 minutes as a single dose</description>
    <arm_group_label>Panel A Mild Renal Impairment</arm_group_label>
    <arm_group_label>Panel B Healthy Participants</arm_group_label>
    <arm_group_label>Panel C Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Panel D Healthy Participants</arm_group_label>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <other_name>PRIMAXIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Caffeine caplet, single 200 mg dose, orally</description>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <other_name>No Doz®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam hcl syrup single 2.0 mg dose by mouth.</description>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <other_name>VERSED®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally</description>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <other_name>PRILOSEC®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Participants of reproductive potential (male or female) must be willing to use
             contraception.

          -  Body Mass Index (BMI) ≤40 kg/m^2

          -  Weight &gt;60 kg at screening visit

          -  No clinically significant abnormality on electrocardiogram (ECG) at screening visit
             and/or prior to administration of the initial dose of study drug

          -  Panels A-D: smokers will be limited to no more that 10 cigarettes per day.

          -  Panels E-H: nonsmoker or has not used nicotine for at least 6 months

          -  In good health (stable health for participants with renal impairment)

        Exclusion criteria

          -  Pregnant or breastfeeding.

          -  History of recent stroke, chronic seizures, or major neurological disorder

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, immunological, respiratory, or genitourinary abnormalities or diseases

          -  History of malignant neoplastic disease. Exceptions: (1) adequately treated
             non-melanomatous skin carcinoma or carcinoma in situ of the cervix; (2) other
             malignancies that have been successfully treated ≥10 years prior to the screening
             visit

          -  Panels A-D: Use of any medication (prescription or non-prescription) or herbal
             remedies (such as St. John's Wort [Hypericum perforatum]) beginning approximately 2
             weeks (or 5 half-lives) prior to administration of the initial dose of study drug to
             the post study visit

          -  Panels E-H: Use of any medication (prescription or non-prescription) or herbal
             remedies (such as St. John's Wort [Hypericum perforatum]) that are inhibitors or
             inducers of CYP1A2, CYP2C19, CYP34A, or substrates of CYP2C19, beginning approximately
             2 weeks (or 5 half-lives) prior to administration of the probe cocktail, until the
             post-study visit

          -  Consumption of greater than 3 glasses of alcoholic beverages (1 glass is approximately
             equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits
             [25 mL/1 ounce]) per day

          -  Consumption of greater than 6 servings (1 serving is approximately equivalent to 120
             mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day

          -  Major surgery, donation or loss of 1 unit of blood (approximately 500 mL), or
             participation in another investigational study within 4 weeks prior to the screening
             visit

          -  History of multiple and/or severe allergies (including latex allergy), or prior
             anaphylactic reaction or intolerability to prescription or non-prescription drugs or
             food

          -  History of hypersensitivity to PRIMAXIN® IV or other beta lactam antibiotic (including
             but not limited to penicillins, cephalosporins, monobactams and carbapenems)

          -  Regular user (including recreational use of drugs [including alcohol]) within
             approximately 12 months of screening visit

          -  History of kidney removal and/or renal transplant

          -  History of Clostridium difficile colitis or known C. difficile colonization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Bhagunde P, Colon-Gonzalez F, Liu Y, Wu J, Xu SS, Garrett G, Jumes P, Lasseter K, Marbury T, Rizk ML, Lala M, Rhee EG, Butterton JR, Boundy K. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin. Br J Clin Pharmacol. 2020 May;86(5):944-957. doi: 10.1111/bcp.14204. Epub 2020 Jan 23.</citation>
    <PMID>31856304</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <results_first_submitted>May 13, 2019</results_first_submitted>
  <results_first_submitted_qc>May 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2019</results_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>MK-7655</mesh_term>
    <mesh_term>Cilastatin, Imipenem Drug Combination</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with varying degrees of renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (HD) [based on estimated glomerular filtration rate (eGFR)], or healthy matched controls were enrolled at 2 study sites in the United States.</recruitment_details>
      <pre_assignment_details>All panels participated in Part 1 of the study. Panels E to H also participated in Part 2 of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panel A: Mild Renal Impairment</title>
          <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="P2">
          <title>Panel B: Healthy Controls to Panel A</title>
          <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="P3">
          <title>Panel C: Moderate Renal Impairment</title>
          <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="P4">
          <title>Panel D: Healthy Controls to Panel C</title>
          <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="P5">
          <title>Panel E: Severe Renal Impairment</title>
          <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.</description>
        </group>
        <group group_id="P6">
          <title>Panel F: Healthy Controls to Panel E</title>
          <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="P7">
          <title>Panel G: ESRD/HD Participants</title>
          <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).</description>
        </group>
        <group group_id="P8">
          <title>Panel H: Healthy Controls to Panel G</title>
          <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1: Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Equipment malfunction before study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1: Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Panel A participated in Part 1, Period 1 only.</participants>
                <participants group_id="P2" count="0">Panel B participated in Part 1, Period 1 only.</participants>
                <participants group_id="P3" count="0">Panel C participated in Part 1, Period 1 only.</participants>
                <participants group_id="P4" count="0">Panel D participated in Part 1, Period 1 only.</participants>
                <participants group_id="P5" count="0">Panel E participated in Part 1, Period 1 and Part 2, Period 1.</participants>
                <participants group_id="P6" count="0">Panel E participated in Part 1, Period 1 and Part 2, Period 1.</participants>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2: Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2: Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0">Panel E participated in Part 1, Period 1 and Part 2, Period 1.</participants>
                <participants group_id="P6" count="0">Panel F participated in Part 1, Period 1 and Part 2, Period 1.</participants>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Base Population consists of 49 randomized participants, including n=1 participant in Panel A who was discontinued prior to receiving study drug due to an equipment malfunction.</population>
      <group_list>
        <group group_id="B1">
          <title>Panel A: Mild Renal Impairment</title>
          <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="B2">
          <title>Panel B: Healthy Controls to Panel A</title>
          <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="B3">
          <title>Panel C: Moderate Renal Impairment</title>
          <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="B4">
          <title>Panel D: Healthy Controls to Panel C</title>
          <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="B5">
          <title>Panel E: Severe Renal Impairment</title>
          <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.</description>
        </group>
        <group group_id="B6">
          <title>Panel F: Healthy Controls to Panel E</title>
          <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="B7">
          <title>Panel G: ESRD/HD Participants</title>
          <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).</description>
        </group>
        <group group_id="B8">
          <title>Panel H: Healthy Controls to Panel G</title>
          <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" spread="3.4"/>
                    <measurement group_id="B2" value="64.5" spread="3.9"/>
                    <measurement group_id="B3" value="68.3" spread="5.0"/>
                    <measurement group_id="B4" value="64.2" spread="5.7"/>
                    <measurement group_id="B5" value="62.8" spread="7.5"/>
                    <measurement group_id="B6" value="60.5" spread="6.4"/>
                    <measurement group_id="B7" value="44.5" spread="7.9"/>
                    <measurement group_id="B8" value="41.5" spread="11.5"/>
                    <measurement group_id="B9" value="59.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf) of MK-7655 in Combination With PRIMAXIN®</title>
        <description>AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf) of MK-7655 in Combination With PRIMAXIN®</title>
          <description>AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="50.0" upper_limit="108"/>
                    <measurement group_id="O2" value="45.0" lower_limit="32.4" upper_limit="62.6"/>
                    <measurement group_id="O3" value="115" lower_limit="79.8" upper_limit="165"/>
                    <measurement group_id="O4" value="52.3" lower_limit="37.7" upper_limit="72.7"/>
                    <measurement group_id="O5" value="236" lower_limit="171" upper_limit="325"/>
                    <measurement group_id="O6" value="48.5" lower_limit="35.3" upper_limit="66.4"/>
                    <measurement group_id="O7" value="414" lower_limit="280" upper_limit="612"/>
                    <measurement group_id="O8" value="44.5" lower_limit="29.1" upper_limit="67.9"/>
                    <measurement group_id="O9" value="78.0" lower_limit="50.3" upper_limit="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Geometric mean ratio (GMR) [Renal Impairment/Healthy Control]</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>2.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>4.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.37</ci_lower_limit>
            <ci_upper_limit>7.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>9.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.45</ci_lower_limit>
            <ci_upper_limit>13.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Concentration at End of Infusion (Ceoi) of MK-7655 in Combination With PRIMAXIN®</title>
        <description>Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
        <time_frame>At 0.5 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Concentration at End of Infusion (Ceoi) of MK-7655 in Combination With PRIMAXIN®</title>
          <description>Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>µM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="13.0" upper_limit="38.7"/>
                    <measurement group_id="O2" value="20.4" lower_limit="12.8" upper_limit="32.7"/>
                    <measurement group_id="O3" value="23.5" lower_limit="14.0" upper_limit="39.4"/>
                    <measurement group_id="O4" value="22.5" lower_limit="14.1" upper_limit="35.9"/>
                    <measurement group_id="O5" value="23.6" lower_limit="15.0" upper_limit="37.2"/>
                    <measurement group_id="O6" value="18.1" lower_limit="11.6" upper_limit="28.4"/>
                    <measurement group_id="O7" value="53.1" lower_limit="30.7" upper_limit="91.9"/>
                    <measurement group_id="O8" value="22.7" lower_limit="12.5" upper_limit="41.0"/>
                    <measurement group_id="O9" value="19.3" lower_limit="11.2" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>2.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>3.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Predicted Clearance (CLpred) of MK-7655 in Combination With PRIMAXIN®</title>
        <description>CLpred is the predicted apparent total body clearance of drug.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Predicted Clearance (CLpred) of MK-7655 in Combination With PRIMAXIN®</title>
          <description>CLpred is the predicted apparent total body clearance of drug.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="55.3" upper_limit="119"/>
                    <measurement group_id="O2" value="133" lower_limit="95.5" upper_limit="185"/>
                    <measurement group_id="O3" value="52.1" lower_limit="36.2" upper_limit="74.9"/>
                    <measurement group_id="O4" value="114" lower_limit="82.3" upper_limit="159"/>
                    <measurement group_id="O5" value="25.3" lower_limit="18.4" upper_limit="34.9"/>
                    <measurement group_id="O6" value="123" lower_limit="90.0" upper_limit="169"/>
                    <measurement group_id="O7" value="14.4" lower_limit="9.77" upper_limit="21.3"/>
                    <measurement group_id="O8" value="135" lower_limit="88.1" upper_limit="206"/>
                    <measurement group_id="O9" value="76.6" lower_limit="49.4" upper_limit="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Predicted Volume of Distribution During the Terminal Phase (VZpred) of MK-7655 in Combination With PRIMAXIN®</title>
        <description>VZpred is the predicted volume of distribution during the terminal phase.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Predicted Volume of Distribution During the Terminal Phase (VZpred) of MK-7655 in Combination With PRIMAXIN®</title>
          <description>VZpred is the predicted volume of distribution during the terminal phase.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="17.6" upper_limit="26.1"/>
                    <measurement group_id="O2" value="21.6" lower_limit="18.2" upper_limit="25.5"/>
                    <measurement group_id="O3" value="22.2" lower_limit="18.4" upper_limit="26.7"/>
                    <measurement group_id="O4" value="21.9" lower_limit="18.5" upper_limit="25.9"/>
                    <measurement group_id="O5" value="20.1" lower_limit="17.1" upper_limit="23.7"/>
                    <measurement group_id="O6" value="22.4" lower_limit="19.0" upper_limit="26.3"/>
                    <measurement group_id="O7" value="16.2" lower_limit="13.3" upper_limit="19.8"/>
                    <measurement group_id="O8" value="17.0" lower_limit="13.6" upper_limit="21.1"/>
                    <measurement group_id="O9" value="55.7" lower_limit="44.5" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>3.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.70</ci_lower_limit>
            <ci_upper_limit>4.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Time of Maximum Plasma Concentration (Tmax) of MK-7655 in Combination With PRIMAXIN®</title>
        <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time of Maximum Plasma Concentration (Tmax) of MK-7655 in Combination With PRIMAXIN®</title>
          <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.48" upper_limit="1.27"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.48" upper_limit="0.52"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.48" upper_limit="0.75"/>
                    <measurement group_id="O4" value="0.49" lower_limit="0.48" upper_limit="0.75"/>
                    <measurement group_id="O5" value="0.48" lower_limit="0.48" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.48" lower_limit="0.48" upper_limit="0.75"/>
                    <measurement group_id="O7" value="0.48" lower_limit="0.08" upper_limit="1.00"/>
                    <measurement group_id="O8" value="0.48" lower_limit="0.48" upper_limit="0.48"/>
                    <measurement group_id="O9" value="0.48" lower_limit="0.48" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Apparent Plasma Half-life (t½) of MK-7655 in Combination With PRIMAXIN®</title>
        <description>Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent Plasma Half-life (t½) of MK-7655 in Combination With PRIMAXIN®</title>
          <description>Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="26.4"/>
                    <measurement group_id="O2" value="1.75" spread="16.6"/>
                    <measurement group_id="O3" value="4.51" spread="25.7"/>
                    <measurement group_id="O4" value="2.10" spread="31.0"/>
                    <measurement group_id="O5" value="8.65" spread="31.0"/>
                    <measurement group_id="O6" value="2.00" spread="10.4"/>
                    <measurement group_id="O7" value="15.6" spread="103.1"/>
                    <measurement group_id="O8" value="1.79" spread="13.9"/>
                    <measurement group_id="O9" value="10.5" spread="100.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: AUC0-inf of Imipenem in Combination With MK-7655</title>
        <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: AUC0-inf of Imipenem in Combination With MK-7655</title>
          <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="58.9" upper_limit="101"/>
                    <measurement group_id="O2" value="55.0" lower_limit="43.5" upper_limit="69.5"/>
                    <measurement group_id="O3" value="101" lower_limit="77.9" upper_limit="130"/>
                    <measurement group_id="O4" value="66.0" lower_limit="52.2" upper_limit="83.3"/>
                    <measurement group_id="O5" value="160" lower_limit="127" upper_limit="201"/>
                    <measurement group_id="O6" value="63.8" lower_limit="51.0" upper_limit="79.9"/>
                    <measurement group_id="O7" value="223" lower_limit="169" upper_limit="293"/>
                    <measurement group_id="O8" value="71.8" lower_limit="53.4" upper_limit="96.5"/>
                    <measurement group_id="O9" value="71.2" lower_limit="54.2" upper_limit="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>2.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.93</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>3.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.39</ci_lower_limit>
            <ci_upper_limit>4.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Ceoi of Imipenem in Combination With MK-7655</title>
        <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
        <time_frame>At 0.5 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Ceoi of Imipenem in Combination With MK-7655</title>
          <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>µM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="22.7" upper_limit="73.2"/>
                    <measurement group_id="O2" value="35.3" lower_limit="21.3" upper_limit="58.5"/>
                    <measurement group_id="O3" value="45.6" lower_limit="26.2" upper_limit="79.5"/>
                    <measurement group_id="O4" value="42.6" lower_limit="25.8" upper_limit="70.4"/>
                    <measurement group_id="O5" value="46.9" lower_limit="28.7" upper_limit="76.5"/>
                    <measurement group_id="O6" value="35.5" lower_limit="21.9" upper_limit="57.6"/>
                    <measurement group_id="O7" value="103" lower_limit="57.1" upper_limit="186"/>
                    <measurement group_id="O8" value="41.8" lower_limit="22.1" upper_limit="79.1"/>
                    <measurement group_id="O9" value="35.9" lower_limit="19.9" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>2.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>4.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: CLpred of Imipenem in Combination With MK-7655</title>
        <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. CLpred is the predicted apparent total body clearance of drug.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: CLpred of Imipenem in Combination With MK-7655</title>
          <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. CLpred is the predicted apparent total body clearance of drug.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" lower_limit="137" upper_limit="236"/>
                    <measurement group_id="O2" value="253" lower_limit="200" upper_limit="320"/>
                    <measurement group_id="O3" value="138" lower_limit="107" upper_limit="179"/>
                    <measurement group_id="O4" value="211" lower_limit="167" upper_limit="266"/>
                    <measurement group_id="O5" value="87.0" lower_limit="69.4" upper_limit="109"/>
                    <measurement group_id="O6" value="218" lower_limit="174" upper_limit="273"/>
                    <measurement group_id="O7" value="62.5" lower_limit="47.5" upper_limit="82.1"/>
                    <measurement group_id="O8" value="194" lower_limit="144" upper_limit="261"/>
                    <measurement group_id="O9" value="195" lower_limit="149" upper_limit="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.65</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: VZpred of Imipenem in Combination With MK-7655</title>
        <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. VZpred is the predicted volume of distribution during the terminal phase.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: VZpred of Imipenem in Combination With MK-7655</title>
          <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. VZpred is the predicted volume of distribution during the terminal phase.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="15.8" upper_limit="28.2"/>
                    <measurement group_id="O2" value="26.1" lower_limit="20.4" upper_limit="33.5"/>
                    <measurement group_id="O3" value="22.3" lower_limit="17.0" upper_limit="29.3"/>
                    <measurement group_id="O4" value="23.4" lower_limit="18.3" upper_limit="30.0"/>
                    <measurement group_id="O5" value="20.0" lower_limit="15.7" upper_limit="25.4"/>
                    <measurement group_id="O6" value="24.8" lower_limit="19.6" upper_limit="31.5"/>
                    <measurement group_id="O7" value="20.5" lower_limit="15.4" upper_limit="27.4"/>
                    <measurement group_id="O8" value="24.9" lower_limit="18.2" upper_limit="34.1"/>
                    <measurement group_id="O9" value="63.3" lower_limit="47.3" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>2.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.93</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tmax of Imipenem in Combination With MK-7655</title>
        <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tmax of Imipenem in Combination With MK-7655</title>
          <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.48" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.48" upper_limit="0.52"/>
                    <measurement group_id="O3" value="0.49" lower_limit="0.48" upper_limit="0.50"/>
                    <measurement group_id="O4" value="0.48" lower_limit="0.48" upper_limit="0.52"/>
                    <measurement group_id="O5" value="0.48" lower_limit="0.48" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.48" lower_limit="0.48" upper_limit="0.75"/>
                    <measurement group_id="O7" value="0.48" lower_limit="0.08" upper_limit="0.48"/>
                    <measurement group_id="O8" value="0.48" lower_limit="0.48" upper_limit="0.48"/>
                    <measurement group_id="O9" value="0.48" lower_limit="0.48" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Apparent t½ of Imipenem in Combination With MK-7655</title>
        <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent t½ of Imipenem in Combination With MK-7655</title>
          <description>Imipenem is 1 of the 2 constituents of PRIMAXIN®. Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="15.2"/>
                    <measurement group_id="O2" value="1.24" spread="10.8"/>
                    <measurement group_id="O3" value="2.18" spread="12.8"/>
                    <measurement group_id="O4" value="1.40" spread="21.1"/>
                    <measurement group_id="O5" value="2.78" spread="11.9"/>
                    <measurement group_id="O6" value="1.32" spread="5.8"/>
                    <measurement group_id="O7" value="3.24" spread="18.7"/>
                    <measurement group_id="O8" value="1.21" spread="13.7"/>
                    <measurement group_id="O9" value="3.20" spread="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: AUC0-inf of Cilastin in Combination With MK-7655</title>
        <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: AUC0-inf of Cilastin in Combination With MK-7655</title>
          <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. AUC0-∞ is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="45.8" upper_limit="112"/>
                    <measurement group_id="O2" value="44.8" lower_limit="30.5" upper_limit="65.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="65.4" upper_limit="153"/>
                    <measurement group_id="O4" value="53.6" lower_limit="36.6" upper_limit="78.6"/>
                    <measurement group_id="O5" value="300" lower_limit="207" upper_limit="436"/>
                    <measurement group_id="O6" value="53.7" lower_limit="37.2" upper_limit="77.6"/>
                    <measurement group_id="O7" value="777" lower_limit="493" upper_limit="1220"/>
                    <measurement group_id="O8" value="56.5" lower_limit="34.5" upper_limit="92.6"/>
                    <measurement group_id="O9" value="205" lower_limit="123" upper_limit="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>5.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.64</ci_lower_limit>
            <ci_upper_limit>8.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>13.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.96</ci_lower_limit>
            <ci_upper_limit>21.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>3.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.32</ci_lower_limit>
            <ci_upper_limit>5.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Ceoi of Cilastin in Combination With MK-7655</title>
        <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
        <time_frame>At 0.5 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Ceoi of Cilastin in Combination With MK-7655</title>
          <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. Ceoi is the observed plasma drug concentration at the end of IV infusion.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>µM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" lower_limit="25.9" upper_limit="72.7"/>
                    <measurement group_id="O2" value="34.8" lower_limit="22.3" upper_limit="54.4"/>
                    <measurement group_id="O3" value="48.7" lower_limit="29.8" upper_limit="79.4"/>
                    <measurement group_id="O4" value="42.9" lower_limit="27.5" upper_limit="66.8"/>
                    <measurement group_id="O5" value="53.3" lower_limit="34.6" upper_limit="82.0"/>
                    <measurement group_id="O6" value="35.8" lower_limit="23.4" upper_limit="54.8"/>
                    <measurement group_id="O7" value="111" lower_limit="65.9" upper_limit="186"/>
                    <measurement group_id="O8" value="44.5" lower_limit="25.4" upper_limit="78.0"/>
                    <measurement group_id="O9" value="41.7" lower_limit="24.8" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>2.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: CLpred of Cilastin in Combination With MK-7655</title>
        <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. CLpred is the predicted apparent total body clearance of drug.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: CLpred of Cilastin in Combination With MK-7655</title>
          <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. CLpred is the predicted apparent total body clearance of drug.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" lower_limit="104" upper_limit="254"/>
                    <measurement group_id="O2" value="259" lower_limit="176" upper_limit="381"/>
                    <measurement group_id="O3" value="116" lower_limit="76.1" upper_limit="178"/>
                    <measurement group_id="O4" value="217" lower_limit="148" upper_limit="318"/>
                    <measurement group_id="O5" value="38.7" lower_limit="26.7" upper_limit="56.2"/>
                    <measurement group_id="O6" value="217" lower_limit="150" upper_limit="313"/>
                    <measurement group_id="O7" value="15.0" lower_limit="9.50" upper_limit="23.6"/>
                    <measurement group_id="O8" value="206" lower_limit="126" upper_limit="337"/>
                    <measurement group_id="O9" value="56.6" lower_limit="33.9" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.18</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: VZpred of Cilastin in Combination With MK-7655</title>
        <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. VZpred is the predicted volume of distribution during the terminal phase.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: VZpred of Cilastin in Combination With MK-7655</title>
          <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. VZpred is the predicted volume of distribution during the terminal phase.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="14.8" upper_limit="24.9"/>
                    <measurement group_id="O2" value="23.9" lower_limit="19.1" upper_limit="30.0"/>
                    <measurement group_id="O3" value="19.4" lower_limit="15.2" upper_limit="24.9"/>
                    <measurement group_id="O4" value="21.4" lower_limit="17.1" upper_limit="26.7"/>
                    <measurement group_id="O5" value="16.9" lower_limit="13.6" upper_limit="21.0"/>
                    <measurement group_id="O6" value="21.2" lower_limit="17.1" upper_limit="26.2"/>
                    <measurement group_id="O7" value="15.9" lower_limit="12.2" upper_limit="20.7"/>
                    <measurement group_id="O8" value="21.0" lower_limit="15.8" upper_limit="28.0"/>
                    <measurement group_id="O9" value="59.1" lower_limit="43.9" upper_limit="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>2.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.16</ci_lower_limit>
            <ci_upper_limit>3.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tmax of Cilastin in Combination With MK-7655</title>
        <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tmax of Cilastin in Combination With MK-7655</title>
          <description>Tmax is the time at which the highest plasma drug concentration was observed.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.50" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.48" upper_limit="0.52"/>
                    <measurement group_id="O3" value="0.49" lower_limit="0.48" upper_limit="0.50"/>
                    <measurement group_id="O4" value="0.48" lower_limit="0.48" upper_limit="0.52"/>
                    <measurement group_id="O5" value="0.48" lower_limit="0.48" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.48" lower_limit="0.48" upper_limit="0.48"/>
                    <measurement group_id="O7" value="0.48" lower_limit="0.08" upper_limit="0.48"/>
                    <measurement group_id="O8" value="0.48" lower_limit="0.48" upper_limit="0.48"/>
                    <measurement group_id="O9" value="0.48" lower_limit="0.48" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Apparent t½ of Cilastin in Combination With MK-7655</title>
        <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
        <time_frame>Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
          <group group_id="O8">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O9">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent t½ of Cilastin in Combination With MK-7655</title>
          <description>Cilastin is 1 of the 2 constituents of PRIMAXIN®. Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, data for Panel G were reported separately for post-dialysis and pre-dialysis.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="31.9"/>
                    <measurement group_id="O2" value="1.08" spread="27.8"/>
                    <measurement group_id="O3" value="2.11" spread="20.5"/>
                    <measurement group_id="O4" value="1.19" spread="28.5"/>
                    <measurement group_id="O5" value="5.08" spread="59.2"/>
                    <measurement group_id="O6" value="1.09" spread="10.7"/>
                    <measurement group_id="O7" value="12.2" spread="118.5"/>
                    <measurement group_id="O8" value="1.14" spread="26.1"/>
                    <measurement group_id="O9" value="12.2" spread="131.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Renal Clearance (CLR) of MK-7655 in Urine</title>
        <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
        <time_frame>Predose to 24 hours postdose</time_frame>
        <population>Treated participants with urine samples who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panel G was not sampled due to limitations in producing urine and was thus not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Renal Clearance (CLR) of MK-7655 in Urine</title>
          <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
          <population>Treated participants with urine samples who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panel G was not sampled due to limitations in producing urine and was thus not included in the analysis.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" spread="16.5"/>
                    <measurement group_id="O2" value="118" spread="19.8"/>
                    <measurement group_id="O3" value="38.4" spread="28.8"/>
                    <measurement group_id="O4" value="110" spread="36"/>
                    <measurement group_id="O5" value="22.3" spread="47.2"/>
                    <measurement group_id="O6" value="107" spread="20.9"/>
                    <measurement group_id="O7" value="110" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: CLR of Imipenem in Urine</title>
        <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
        <time_frame>Predose to 24 hours postdose</time_frame>
        <population>Treated participants with urine samples who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panel G was not sampled due to limitations in producing urine and was thus not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: CLR of Imipenem in Urine</title>
          <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
          <population>Treated participants with urine samples who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panel G was not sampled due to limitations in producing urine and was thus not included in the analysis.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="14.6"/>
                    <measurement group_id="O2" value="115" spread="18.4"/>
                    <measurement group_id="O3" value="41.1" spread="23.8"/>
                    <measurement group_id="O4" value="109" spread="29.2"/>
                    <measurement group_id="O5" value="17.4" spread="44.7"/>
                    <measurement group_id="O6" value="104" spread="10.5"/>
                    <measurement group_id="O7" value="99.1" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: CLR of Cilastin in Urine</title>
        <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
        <time_frame>Predose to 24 hours postdose</time_frame>
        <population>Treated participants with urine samples who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panel G was not sampled due to limitations in producing urine and was thus not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: Healthy Controls to Panel A</title>
            <description>Healthy control participants were matched specifically to participants in Panel A and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel D: Healthy Controls to Panel C</title>
            <description>Healthy control participants were matched specifically to participants in Panel C and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: CLR of Cilastin in Urine</title>
          <description>CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.</description>
          <population>Treated participants with urine samples who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panel G was not sampled due to limitations in producing urine and was thus not included in the analysis.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" spread="29.1"/>
                    <measurement group_id="O2" value="144" spread="21.9"/>
                    <measurement group_id="O3" value="59.6" spread="29.4"/>
                    <measurement group_id="O4" value="136" spread="23.9"/>
                    <measurement group_id="O5" value="24.5" spread="50.5"/>
                    <measurement group_id="O6" value="140" spread="24.4"/>
                    <measurement group_id="O7" value="146" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Plasma AUC0-∞ of Caffeine as a Probe Substrate of Cytochrome P450 Enzyme (CYP)1A2</title>
        <description>Caffeine was selected as a substrate of CYP1A2. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
        <time_frame>Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose</time_frame>
        <population>Treated participants with severe renal deficiency or ESRD and their matched controls (Panels E-H) who complied with the protocol enough to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panels A-D were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg 1 hour predialysis (Period 1) in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg 24 hours predialysis (Period 2) in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Plasma AUC0-∞ of Caffeine as a Probe Substrate of Cytochrome P450 Enzyme (CYP)1A2</title>
          <description>Caffeine was selected as a substrate of CYP1A2. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
          <population>Treated participants with severe renal deficiency or ESRD and their matched controls (Panels E-H) who complied with the protocol enough to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panels A-D were not included in the analysis.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336" lower_limit="232" upper_limit="489"/>
                    <measurement group_id="O2" value="221" lower_limit="156" upper_limit="314"/>
                    <measurement group_id="O3" value="190" lower_limit="138" upper_limit="264"/>
                    <measurement group_id="O4" value="200" lower_limit="144" upper_limit="277"/>
                    <measurement group_id="O5" value="300" lower_limit="211" upper_limit="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Plasma AUC0-∞ of Midazolam as a Probe Substrate of Cytochrome P450 Enzyme (CYP)3A4</title>
        <description>Midazolam was selected as a substrate of CYP3A4. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
        <time_frame>Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose</time_frame>
        <population>Treated participants with severe renal deficiency or ESRD and their matched controls (Panels E-H) who complied with the protocol enough to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panels A-D were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg 1 hour predialysis (Period 1) in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg 24 hours predialysis (Period 2) in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Plasma AUC0-∞ of Midazolam as a Probe Substrate of Cytochrome P450 Enzyme (CYP)3A4</title>
          <description>Midazolam was selected as a substrate of CYP3A4. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
          <population>Treated participants with severe renal deficiency or ESRD and their matched controls (Panels E-H) who complied with the protocol enough to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panels A-D were not included in the analysis.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.130" lower_limit="0.0730" upper_limit="0.230"/>
                    <measurement group_id="O2" value="0.121" lower_limit="0.0707" upper_limit="0.207"/>
                    <measurement group_id="O3" value="0.0681" lower_limit="0.0413" upper_limit="0.112"/>
                    <measurement group_id="O4" value="0.0700" lower_limit="0.0425" upper_limit="0.115"/>
                    <measurement group_id="O5" value="0.114" lower_limit="0.0664" upper_limit="0.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Plasma AUC0-∞ of Omeprazole as a Probe Substrate of Cytochrome P450 Enzyme (CYP)2C19</title>
        <description>Omeprazole was selected as a substrate of CYP2C19. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
        <time_frame>Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose</time_frame>
        <population>Treated participants with severe renal deficiency or ESRD and their matched controls (Panels E-H) who complied with the protocol enough to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panels A-D were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel F: Healthy Controls to Panel E</title>
            <description>A subset of healthy control participants was matched specifically to participants in Panel E and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel G: ESRD/HD Period 1 Postdialysis</title>
            <description>Participants with ESRD/HD receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg 1 hour predialysis (Period 1) in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg 24 hours predialysis (Period 2) in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel H: Healthy Controls to Panel G</title>
            <description>Healthy control participants were matched specifically to participants in Panel G and received a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Plasma AUC0-∞ of Omeprazole as a Probe Substrate of Cytochrome P450 Enzyme (CYP)2C19</title>
          <description>Omeprazole was selected as a substrate of CYP2C19. AUC0-∞ was determined in participants with severe renal impairment and ESRD/HD participants.</description>
          <population>Treated participants with severe renal deficiency or ESRD and their matched controls (Panels E-H) who complied with the protocol enough to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, Panels A-D were not included in the analysis.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.10" lower_limit="3.34" upper_limit="24.8"/>
                    <measurement group_id="O2" value="6.20" lower_limit="2.85" upper_limit="13.5"/>
                    <measurement group_id="O3" value="4.56" lower_limit="2.16" upper_limit="9.59"/>
                    <measurement group_id="O4" value="4.08" lower_limit="1.97" upper_limit="8.44"/>
                    <measurement group_id="O5" value="5.03" lower_limit="2.18" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>1.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR (Renal Impairment/Healthy Control)</non_inferiority_desc>
            <param_type>GMR</param_type>
            <param_value>0.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parts 1 and 2: Percentage of Participants With ≥1 Adverse Events (AEs)</title>
        <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 14 days after the last dose of study drug in Part 2 (up to 11 weeks)</time_frame>
        <population>All enrolled participants are included in the safety analysis according to the treatment received. Per protocol, healthy matched controls were pooled for the purpose of the safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Mild Renal Impairment</title>
            <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel C: Moderate Renal Impairment</title>
            <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel E: Severe Renal Impairment</title>
            <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel G: ESRD/HD Participants</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Period 1) and predialysis (Period 2) in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Healthy Matched Controls (Part 1)</title>
            <description>Healthy matched controls receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV. Data from all of the Healthy Control subsets from Part 1 was pooled for safety analyses.</description>
          </group>
          <group group_id="O6">
            <title>Panel E: Severe Renal Impairment (Part 2)</title>
            <description>Participants with Participants with an eGFR &lt;30 mL/min/1.73m² receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg postdialysis (Period 1) and predialysis (Period 2) in Part 2.</description>
          </group>
          <group group_id="O7">
            <title>Panel G: ESRD/HD (Part 2)</title>
            <description>Participants with ESRD/HD receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg postdialysis (Period 1) and predialysis (Period 2) in Part 2.</description>
          </group>
          <group group_id="O8">
            <title>Healthy Matched Controls (Part 2)</title>
            <description>Healthy matched controls receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg postdialysis (Period 1) and predialysis (Period 2) in Part 2. Data from all of the Healthy Control subsets from Part 2 was pooled for safety analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Parts 1 and 2: Percentage of Participants With ≥1 Adverse Events (AEs)</title>
          <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>All enrolled participants are included in the safety analysis according to the treatment received. Per protocol, healthy matched controls were pooled for the purpose of the safety analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dialysis Clearance (CLD) of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)</title>
        <description>The CLD of MK-7655 was determined in ESRD/HD participants for 4.5 hours during HD. The formula for calculating CLD was: CLd = (1-Hct)*QB*[(pre-dialyzer concentration - post-dialyzer concentration) / (pre-dialyzer concentration)] where QB=350 mL/min and Hct=hematocrit.</description>
        <time_frame>1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, only Panel G participants requiring HD were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Dialysis Clearance (CLD) of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)</title>
          <description>The CLD of MK-7655 was determined in ESRD/HD participants for 4.5 hours during HD. The formula for calculating CLD was: CLd = (1-Hct)*QB*[(pre-dialyzer concentration - post-dialyzer concentration) / (pre-dialyzer concentration)] where QB=350 mL/min and Hct=hematocrit.</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, only Panel G participants requiring HD were included in the analysis.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.0 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extraction Coefficient of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)</title>
        <description>The extraction coefficient of MK-7655 was determined in ESRD/HD participants for 4.5 hours during HD. The formula for calculating extraction coefficient was: Extraction Coefficient = ABS[100*(post-dialyzer concentration - pre-dialyzer concentration) / pre-dialyzer concentration].</description>
        <time_frame>1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours postdose</time_frame>
        <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, only Panel G is included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel G: ESRD/HD Period 2 Predialysis</title>
            <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Extraction Coefficient of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)</title>
          <description>The extraction coefficient of MK-7655 was determined in ESRD/HD participants for 4.5 hours during HD. The formula for calculating extraction coefficient was: Extraction Coefficient = ABS[100*(post-dialyzer concentration - pre-dialyzer concentration) / pre-dialyzer concentration].</description>
          <population>Treated participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model, are included. Per protocol, only Panel G is included in the analysis.</population>
          <units>Extraction coefficient</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.0 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after the last dose of study drug in Part 2 (up to 11 weeks)</time_frame>
      <desc>All enrolled participants are included in the safety analysis according to the treatment received. Per protocol, healthy matched controls were pooled for the purpose of the safety analysis. AEs were reported separately for Panels E, G, and matching controls during Parts 1 and 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panel A: Mild Renal Impairment</title>
          <description>Participants with an eGFR of &gt;50 to &lt;80 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="E2">
          <title>Panel C: Moderate Renal Impairment</title>
          <description>Participants with an eGFR of 30 to 50 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.</description>
        </group>
        <group group_id="E3">
          <title>Panel E: Severe Renal Impairment</title>
          <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.</description>
        </group>
        <group group_id="E4">
          <title>Panel G: ESRD/HD Participants</title>
          <description>Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).</description>
        </group>
        <group group_id="E5">
          <title>Healthy Matched Controls</title>
          <description>Healthy matched controls receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. For AE reporting, all healthy control participants in Part 1 are pooled into a single arm.</description>
        </group>
        <group group_id="E6">
          <title>Panel E: Severe Renal Impairment (Part 2)</title>
          <description>Participants with an eGFR &lt;30 mL/min/1.73m² receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.</description>
        </group>
        <group group_id="E7">
          <title>Panel G: ESRD/HC (Part 2)</title>
          <description>Participants with ESRD/HD receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.</description>
        </group>
        <group group_id="E8">
          <title>Healthy Matched Controls (Part 2)</title>
          <description>Healthy matched controls receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg in Part 2. For AE reporting, all healthy control participants in Part 2 are pooled into a single arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v. 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

